Observational study finds gut bacteria linked to cancer treatment outcomes in patients — Evidence Review

Gut bacteria profiles in cancer patients may predict survival and chemotherapy side effects even before treatment begins, according to a large observational study; these findings are consistent with growing evidence linking the gut microbiome to cancer outcomes and therapy response. Most related studies support the idea that specific microbiome patterns are associated with cancer type, prognosis, and treatment tolerance, though the details and implicated bacteria can vary across studies and cancer types (1, 3, 4, 5, 11, 14).

• The new findings align with prior research showing that gut microbiome composition influences response to immunotherapy and chemotherapy, with certain bacteria associated with better or worse outcomes in cancers such as melanoma, gastrointestinal, and hepatobiliary cancers (1, 2, 3, 5, 14).
• Several studies highlight that distinct bacterial species can modulate drug efficacy and toxicity, supporting the current study’s observation that microbial genes may influence chemotherapy side effects (12, 13, 14, 15).
• While the specific microbial signatures identified in this study differ in detail from previous work, the overall conclusion that the microbiome is an important, underappreciated factor in cancer therapy is widely echoed in the literature (4, 11, 12, 14, 15).

Study Overview and Key Findings

Research into the role of the gut microbiome in cancer is gaining urgency as cancer incidence rises among younger adults and as clinicians seek to better predict patients' responses to therapy. This new observational study, conducted by Mayo Clinic and published in Cell, analyzed stool samples from over 1,300 cancer patients before treatment, linking microbial patterns to cancer type, age at diagnosis, survival, and chemotherapy side effects. The study’s scale and pre-treatment sampling allowed the team to investigate not just associations at diagnosis but also how microbial differences may relate to patient outcomes and treatment tolerance—an approach that distinguishes it from many earlier, smaller studies.

Property	Value
Study Year	2026
Organization	Mayo Clinic
Journal Name	Cell
Authors	Lu Yang, Vaidhvi Singh, Brent J. Gawey, Jason P. Sinnwell, Stephen Johnson, Elle C. Billings, Trena M. Van Gorp, Jonathan J. Harrington, Michael Q. Slama, Lisa M. Till, Manavjot Singh, Thoshik R. Samineni, Mojun Zhu, Krishna R. Kalari, Gianrico Farrugia, Jun Chen, Ruben A.T. Mars, Purna C. Kashyap
Population	Patients with various types of cancer
Sample Size	n=1,364
Methods	Observational Study
Outcome	Microbial differences, survival rates, chemotherapy side effects
Results	341 bacterial species linked to five cancer groups identified.

Literature Review: Related Studies

To understand how the new findings fit into the broader research landscape, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant studies:

1. gut bacteria cancer treatment outcomes
2. bacterial species cancer group associations
3. microbiome effects on chemotherapy response

Below, we organize key insights from the literature into major thematic questions.

Topic	Key Findings
How does the gut microbiome influence cancer therapy response and side effects?	- Gut microbiome composition predicts clinical outcomes and immune-related adverse events in cancer immunotherapy, with certain bacteria linked to improved response or toxicity (1, 2, 3, 5, 11, 12, 14, 15). - Modulation of gut microbiota (e.g., through fecal transplantation or diet) can enhance therapy efficacy and reduce toxicity (4, 13, 14, 15).
Are specific bacterial species or community patterns associated with particular cancer types or outcomes?	- Distinct gut microbiome patterns are associated with different cancers and even with molecular subtypes, such as in colorectal and breast cancers (9, 10). - Certain bacterial taxa (e.g., Faecalibacterium, Lachnospiraceae, Veillonellaceae) correlate with prognosis and response to therapy; however, the direction and significance can differ by cancer type (2, 5, 9, 10).
Can gut microbiome profiles be used as biomarkers or therapeutic targets in cancer?	- Microbiome signatures show diagnostic, prognostic, and therapeutic potential, including for predicting immunotherapy and chemotherapy response (2, 4, 11, 12, 14, 15). - Modulating the microbiome (e.g., via transplantation, diet, supplementation) is being explored to improve treatment outcomes (4, 13, 14, 15).
What mechanisms underlie microbiome effects on cancer development and therapy?	- Microbial metabolites (e.g., 3-IAA, short-chain fatty acids) and immune modulation are key mechanisms by which gut microbes influence cancer progression and therapy response (6, 12, 13, 14, 15). - Bacteria can modulate drug metabolism and immune responses, affecting both efficacy and side effects (12, 13, 14).

---

How does the gut microbiome influence cancer therapy response and side effects?

Numerous studies indicate that the composition of the gut microbiome is a significant factor in determining how patients respond to cancer therapy, including immunotherapies and chemotherapies, as well as their risk for treatment-related side effects. The new Mayo Clinic study extends these observations by identifying specific microbial differences that correlate with both survival and chemotherapy tolerance before treatment begins.

• Gut microbial patterns can predict both positive and negative responses to immune checkpoint inhibitors and chemotherapies (1, 2, 3, 5, 11, 14, 15).
• Microbiome composition prior to therapy has been shown to be linked to clinical outcomes in studies of melanoma, gastrointestinal, and hepatobiliary cancers (1, 3, 5).
• Certain bacteria, such as Lachnospiraceae and Veillonella, can be associated with either increased or decreased survival, depending on the cancer context (5, 9).
• The role of gut microbiota in mediating side effects (e.g., chemotherapy-induced diarrhea) is increasingly recognized, with the current study highlighting bacterial gene capacity for drug metabolism as a potential predictor (14, 15).

Are specific bacterial species or community patterns associated with particular cancer types or outcomes?

Research has identified that not only does the overall diversity and composition of the gut microbiome differ by cancer type, but specific bacterial taxa are associated with particular cancers and even with subtypes within a cancer type. The Mayo Clinic study finds age- and cancer-specific microbial patterns, echoing and expanding on these previous findings.

• Different cancers, such as colorectal and breast, show unique microbial signatures, including associations with Veillonella, Clostridium, and others (9, 10).
• Microbiome patterns can distinguish between cancer subtypes, such as consensus molecular subtypes in colorectal cancer or prognostic features in breast cancer (9, 10).
• The specific direction of association (protective or adverse) can differ for the same taxa in different cancers or subgroups (5, 9, 10).
• The findings support the idea that microbial signatures may help stratify patients and guide individualized care (2, 4, 10).

Can gut microbiome profiles be used as biomarkers or therapeutic targets in cancer?

There is growing interest in leveraging microbiome profiles for diagnostic and prognostic purposes, as well as for therapeutic modulation to improve cancer outcomes. The current study’s identification of microbial genes associated with survival and side effects further supports the potential utility of microbiome-based biomarkers and interventions.

• Microbial signatures have been shown to predict response to immunotherapy and chemotherapy, and machine learning approaches have been used to develop predictive models (2, 4, 11, 12, 14, 15).
• Clinical trials are exploring interventions such as fecal microbiota transplantation and dietary modification to shape the microbiome for therapeutic benefit (4, 13, 14, 15).
• Microbiome-based biomarkers are not yet standardized across studies or cancer types, highlighting the need for further research (2, 4, 14, 15).
• The translational potential of these findings includes both risk stratification and the development of microbiome-modulating therapies (4, 13, 14, 15).

What mechanisms underlie microbiome effects on cancer development and therapy?

Mechanistic studies have begun to unravel how the gut microbiome influences cancer progression and response to treatment, with evidence pointing to both metabolic and immune-mediated pathways. The Mayo Clinic study’s findings on bacterial genes linked to drug metabolism add to this mechanistic understanding.

• Microbial metabolites, such as short-chain fatty acids and 3-IAA, can modulate immune responses and cancer cell susceptibility to therapy (6, 12, 13, 14, 15).
• Bacteria may affect the pharmacokinetics and pharmacodynamics of chemotherapeutic agents, influencing efficacy and toxicity (12, 13, 14).
• The interaction between microbial communities, host immunity, and cancer cells is complex and context-dependent (6, 12, 14, 15).
• Direct and indirect effects of bacteria on tumor microenvironments and systemic immune responses are being actively explored (6, 12, 14, 15).

Future Research Questions

While significant progress has been made in linking the gut microbiome to cancer outcomes and therapy response, many questions remain. Further research is needed to clarify causality, standardize biomarkers, and develop effective interventions. Addressing these questions could enable more personalized and effective cancer treatments.

Research Question	Relevance
Can modifying the gut microbiome before treatment improve cancer outcomes?	Understanding whether pre-treatment interventions (e.g., diet, probiotics, transplantation) can enhance therapy efficacy or reduce toxicity would inform clinical practice and prevention strategies (4, 13, 14, 15).
Which specific microbial species or genes are causally linked to cancer therapy response?	Identifying causal relationships (rather than associations) is crucial for developing targeted microbiome-based therapies and reliable clinical biomarkers (2, 4, 12, 15).
Are microbiome-based biomarkers for cancer outcomes consistent across populations and cancer types?	Variation in microbiome signatures across studies and populations highlights the need to determine the generalizability and reproducibility of potential biomarkers (1, 2, 4, 10, 14).
How do gut microbiome profiles change during and after cancer therapy?	Longitudinal studies are needed to understand dynamic changes in the microbiome, which may affect both short-term side effects and long-term outcomes (3, 5, 14).
What are the mechanisms by which the microbiome modulates chemotherapy toxicity?	Unraveling these mechanisms could lead to strategies for predicting and preventing adverse effects, thereby improving patient quality of life and therapy adherence (12, 13, 14, 15).